Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.
2024
Cancer charity welcomes new smartphone app for melanoma patients
The app, being developed by the University of Aberdeen, will help people previously treated for melanoma examine their skin regularly to reduce their anxiety and help catch any recurrence of the disease.
Relatlimab/Nivolumab in Melanoma Improves Brain Metastasis–Free Survival
Ahmad Tarhini, MD, PhD: This was a first-line patient population with untreated metastatic melanoma who were randomly assigned 1:1 to a fixed-dose combination of nivolumab at 480 mg and relatlimab at 160 mg [Opdualag]. This was a fixed-dose single infusion on the study given over 60 minutes.
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib………….
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM.